"
Team:SupBiotech-Paris/Acknowledgement
From 2009.igem.org
(Difference between revisions)
| Line 2: | Line 2: | ||
{{Template:Supbiotechparis}} | {{Template:Supbiotechparis}} | ||
| - | + | ||
| + | We want to acknowledge : | ||
| + | '''UMR8121 from the Gustave Roussy Institute''' | ||
| + | Thanks a lot to: | ||
| + | *Lluis Mir | ||
| + | *Karim | ||
'''Our Sponsors''' | '''Our Sponsors''' | ||
| - | *Embassy of France | + | *'''Embassy of France in Washington''' [http://fr.ambafrance-us.org/spip.php?rubrique=[Link]] |
| - | *Eurogentec | + | *'''Eurogentec''' [http://www.eurogentec.com/eu-home.html [Link]] |
| - | *Takara | + | *'''Takara''' [http://www.takarabioeurope.com/ [Link]] |
| - | * | + | *'''Clonetec'''[http://www.clontech.com/ [Link]] |
| + | *'''Promega''' [http://www.promega.com/ [Link]] | ||
| + | *'''Sigma-Aldrich''' [http://www.sigmaaldrich.com/ [Link]] | ||
| + | *'''Qiagen''' [http://www1.qiagen.com/ [Link]] | ||
Revision as of 14:16, 19 August 2009
Project
Introduction Current therapies Gene therapies DVS Concept Tissue Vector Cell Vector Therapeutic plasmid Conclusion Implementation Tissue targeting Antitumor action Treatment modeling Conclusion
Ressources
BioBricks Material & Method Bibliography
Ethics & Safety
We want to acknowledge :
UMR8121 from the Gustave Roussy Institute
Thanks a lot to:
- Lluis Mir
- Karim
Our Sponsors
- Embassy of France in Washington [http://fr.ambafrance-us.org/spip.php?rubrique=[Link]]
- Eurogentec [http://www.eurogentec.com/eu-home.html [Link]]
- Takara [http://www.takarabioeurope.com/ [Link]]
- Clonetec[http://www.clontech.com/ [Link]]
- Promega [http://www.promega.com/ [Link]]
- Sigma-Aldrich [http://www.sigmaaldrich.com/ [Link]]
- Qiagen [http://www1.qiagen.com/ [Link]]
